Table 1 Baseline characteristics of subjects in the placebo and tiotropium arms of the UPLIFT trial included in the analysis of time trends in bronchodilator responses over the course of the trial
Characteristic | Placebo (N = 2463) | Tiotropium (N = 2579) |
|---|---|---|
Age, yrs, mean (SD) | 64.2 (8.39) | 64.3 (8.39) |
>65 yrs, N (%) | 1158 (47.0%) | 1223 (47.4%) |
≤65 yrs, N (%) | 1305 (53.0%) | 1356 (52.6%) |
Gender, male, N (%) | 1852 (75.2%) | 1965 (76.2%) |
Pre-bronchodilator FEV1, L, mean (SD) | 1.12 (0.40) | 1.11 (0.40) |
Pre-bronchodilator FEV1, % predicted, mean (SD) | 39.9 (11. 8) | 39.8 (11.9) |
Post-bronchodilator FEV1, L, mean (SD) | 1.35 (0.44) | 1.34 (0.43) |
Post-bronchodilator FEV1, % predicted, mean (SD) | 48.2 (12.4) | 48.1 (12.5) |
Pre-bronchodilator FVC, L, mean (SD) | 2.66 (0.83) | 2.64 (0.80) |
Pre-bronchodilator FVC, % predicted, mean (SD) | 75.4 (18.0) | 74.8 (17.9) |
Post-bronchodilator FVC, L, mean (SD) | 3.13 (0.90) | 3.11 (0.86) |
Post-bronchodilator FVC, % predicted, mean (SD) | 88.7 (18.7) | 88.2 (18.5) |
Pre-bronchodilator FEV1/FVC ratio, %, mean (SD) | 42.5 (10.3) | 42.7 (10.4) |
Post-bronchodilator FEV1/FVC ratio, %, mean (SD) | 43.8 (10.5) | 43.9 (10.7) |
Smoking status | ||
Sustained ex-smoker, N (%) | 1471 (59.7%) | 1502 (58.2%) |
Intermittent smoker, N (%) | 679 (27.6%) | 761 (29.5%) |
Continuing smoker, N (%) | 313 (12.7%) | 316 (12.3%) |
Pack-yrs smoking, mean (SD) | 48.0 (27.9) | 49.0 (28.0) |
GOLD grade of airflow obstruction | ||
Grade I/II, N (%) | 1179 (48.6%) | 1226 (48.3%) |
Grade III, N (%) | 1059 (43.6%) | 1118 (44.0%) |
Grade IV, N (%) | 189 (7.79%) | 197 (7.75%) |
Use of Inhaled Corticosteroids at baseline | ||
Yes | 1506 (61.1%) | 1581 (61.3%) |
No | 957 (38.9%) | 998 (38.7%) |
SGRQ total scores, mean (SD) | 45.2 (17.2) | 45.0 (17.0) |